Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

CervoMed to Participate in the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit

globenewswire.com
CRVO CervoMed announced management will participate in a fireside chat and investor meetings at an H.C. Wainwright summit. The article details their drug candidate neflamapimod and ongoing clinical trials, but does not provide new information that would sway sentiment.

CervoMed to Participate in the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit BOSTON, June 12, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today announced that Company management will participate in a fireside chat and one-on-one investor meetings at the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit, being held virtually on Monday, June 15, 2026.

Presentation Details

Format: Fireside Chat

Date: Monday, June 15, 2026

Time: 7:00 – 7:30 AM ET

Webcast Link: https://journey.ct.events/view/9162603c-eb01-4cb3-85b7-36814fad7928

The webcast of the fireside chat will be accessible in the Investor section of the CervoMed website https://www.cervomed.com/.

About CervoMed

CervoMed is a clinical-stage company developing treatments for age-related brain disorders. Its lead drug candidate, neflamapimod, is an oral small molecule targeting critical disease processes underlying degenerative disorders of the brain by inhibiting a key enzyme involved in neuroinflammation and neurodegeneration. CervoMed’s recently completed Phase 2b RewinD-LB trial evaluated neflamapimod in patients with DLB, enriched for those without AD co-pathology, and the Company announced alignment with the FDA on a potential registration path for neflamapimod in DLB in November 2025. Initiation of a Phase 3 trial in DLB is subject to the establishment of a partnership and/or additional financing. CervoMed also recently completed enrollment in its ongoing Phase 2a clinical trial evaluating neflamapimod in nfvPPA, a subtype of frontotemporal disorders, from which interim biomarker data is anticipated in the early fourth quarter of 2026, and expects the first patient to be dosed with neflamapimod in the EXPERTS-ALS Phase 2a clinical trial in the fourth quarter of 2026.

Contacts

Media:

Lisa Guiterman

Biongage Communications

lisa.guiterman@gmail.com

202-330-3431

Investor Relations:

Argot Partners

cervomed@argotpartners.com

212-600-1902